Longevity & AgingNext-Gen Senolytics Move Beyond Pills to Precision Immune and Molecular Targeting
Cellular senescence drives aging and chronic disease, but first-generation senolytics like navitoclax and dasatinib-quercetin carry serious limitations including thrombocytopenia, poor bioavailability, and inconsistent efficacy. This 2026 NPJ Aging review surveys three next-generation precision strategies: immune-based senolysis using CAR-T cells and checkpoint blockade targeting surface markers like uPAR and GD3 ganglioside; tissue-targeted PROTAC molecules that recruit E3 ligases to degrade anti-apoptotic BCL-xL with reduced systemic toxicity; and microbiome-epigenetic modulation where gut-derived short-chain fatty acids like butyrate suppress SASP and enhance drug transporter activity. While highly promising, each approach faces hurdles including manufacturing complexity, immunopathology risk, off-target effects, and limited clinical data.
